Problems in the treatment of bacterial sexually transmitted diseases
Abstract:
Although most bacterial sexually transmitted diseases (STDs) can be effectively treated, currently available regimens are far from ideal. Increasingly widespread plasmid-mediated resistance to the penicillins limits the use of these agents in the treatment of Neisseria gonorrhoeae and Hemophilus ducreyi infections. Chromosomally mediated antimicrobial resistance to the tetracyclines, penicillins, erythromycins, and sulfonamides further limits therapeutic options in the treatment of gonorrhea, and plasmid-mediated resistance to sulfonamides and tetracyclines is frequent in H. ducreyi infections. In patients with Chlamydia trachomatis infections, effective regimens that can more easily be complied with (shorter duration, less frequent dosing) are needed, as are effective alternative regimens for use in pregnancy and in infants. In selected STDs that are polymicrobial (pelvic inflammatory disease and bacterial vaginosis, for example) or that often present simultaneously (gonorrhea-chlamydia, gonorrhea-syphilis, chancroid-syphilis), single-drug regimens that are effective against several genital pathogens would be ideal. Only limited therapeutic alternatives are available for some STDs, especially in pregnant women or in patients with penicillin allergy. Thus, antimicrobial resistance, drug toxicity, poor compliance, limited alternatives in pregnancy or allergy, and the lack of single agents possessing a broad spectrum of activity against multiple genital pathogens limit currently available therapy.
Insights
Current treatments for bacterial sexually transmitted diseases (STDs) are suboptimal due to widespread antimicrobial resistance and limited options for specific populations. New, broader-spectrum therapies are needed to combat resistant pathogens and improve patient compliance.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Most bacterial sexually transmitted diseases (STDs) have available treatments, but these regimens are not ideal.
- Antimicrobial resistance is a growing concern, limiting treatment options for common STDs like gonorrhea and chancroid.
- Current treatments for Chlamydia trachomatis infections require improvement in terms of compliance and options for pregnant individuals.
Purpose of the Study:
- To review the limitations of current antimicrobial therapies for bacterial STDs.
- To highlight the challenges posed by antimicrobial resistance, drug toxicity, and compliance issues.
- To identify the need for improved and broader-spectrum treatment options for STDs.
Main Methods:
- Literature review of current antimicrobial resistance patterns in STDs.
- Analysis of therapeutic limitations, including drug toxicity and compliance.
- Examination of treatment challenges in specific populations (e.g., pregnant women, infants).
Main Results:
- Widespread plasmid-mediated resistance to penicillins affects Neisseria gonorrhoeae and Hemophilus ducreyi.
- Chromosomal resistance to multiple antibiotic classes limits gonorrhea treatment.
- Resistance to sulfonamides and tetracyclines is frequent in H. ducreyi infections.
- Need for improved regimens for Chlamydia trachomatis, especially for pregnant women.
- Limited alternatives exist for STDs in pregnant women or those with penicillin allergies.
Conclusions:
- Antimicrobial resistance, drug toxicity, poor compliance, and limited treatment alternatives hinder effective STD management.
- There is a critical need for novel therapeutic strategies, including single-agent broad-spectrum drugs, to address current STD treatment challenges.
Related Concept Videos
01:26Sexually Transmitted Infections
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
01:26Urine Studies II: Urine Culture and Sensitivity Test
01:23Genital Herpes
01:28Amebiasis
01:18Trichomoniasis